Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Caris Life Sciences Earnings Call: Key Takeaways

Caris Life Sciences delivered record Q3 2026 revenue of $275.4M, up 27%, while raising full-year guidance and expanding its oncology platform into monitoring and MRD markets.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue up 27% to $275.4M; molecular profiling up 27% to $262.7M.
Mgmt ConfidenceHigh confidence in commercial strategy and accelerating volume growth trends into Q4.
Demand VisibilityStrong momentum with 65,000 cases expected in Q4; 75% orders via EMR.
Margin TrendsGross margin at 66%; sixth consecutive quarter of positive adjusted EBITDA.
Op. LeverageOperating expenses grew 48% to $163M, funding sales force and marketing.
Pricing PowerBlended ASP $4,272 up 5%; base ASP $3,990 up 19% pre-true-ups.
Vol vs PriceGrowth driven by 21% volume increase and 19% pre-true-up ASP expansion.
Segment GrowthClinical therapy selection volume grew 21%; R&D services revenue up 37%.
New ClientsPrecision Oncology Alliance expanded to 102 sites; 3,500 physicians ordering via EMR.
Capex & DebtCapEx of $17.5M; $769M cash; $10M stock repurchased in Q3.
RegulatoryPAMA rate for Caris Assure increased to $5,250 effective January 2027.
CommentaryPhilosophy of 'deeper not cheaper' prioritizing comprehensive 23,000-gene whole exome sequencing.
New LaunchesLaunched Caris Assure monitoring; Caris Confirm MRD launch scheduled for December.

Growth

Total revenue grew 27% to $275.4M; clinical volume rose 21% to 61,500 cases.

Outlook

Raised FY2026 revenue guidance to $1.04B-$1.05B; targeting 65,000 clinical cases in Q4.

Risks

Management evaded specific volume/revenue breakouts for new products like Caris Detect and Chromoseq.

Source

The company's earnings call, NASDAQ: CAI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Caris Life Sciences, Inc.: key numbers

Share price
$21.00Close, Nov 16
Market cap
$6.02B
Shares outstanding
286.78MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Caris Life Sciences, Inc.

All →
5:02 PM ET 10-Q
Financial Results ▶ Call

Caris Life Sciences Q3 2026 Results: Net Income $15.2M, Down 37.3% YoY

Caris Life Sciences reported total revenue of $755.2 million for the nine months ended September 30, 2026, a significant increase from $519.1 million in the prior year period. The company achieved a net income from operations of $51.5 million for the first nine months of 2026, compared to an operating loss of $43.3 million in 2025, driven primarily by growth in molecular profiling services.

Key figure
Net income $15.2M · -37.3% YoY
4:13 PM ET 8-K
Financial Results

Caris Life Sciences Financial Results

Caris Life Sciences reported Q3 2026 revenue of $275.4 million, a 27% increase year-over-year, driven by strong molecular profiling clinical case volume. The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion and reported positive net income of $15.3 million for the quarter.

Term
Q3 2026

“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year. Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey.”

David Dean Halbert, Founder, Chairman and CEO
4:40 PM ET 8-K
Investor Presentation

Caris Life Sciences Investor Presentation

Caris Life Sciences announced that its management team will use a formal investor presentation for meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference beginning September 14, 2026. The presentation will be made available on the company's investor relations website.

Counterparty
Morgan Stanley 24th Annual Global Healthcare Conference

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.